Paradigm Biocapital Advisors LP Galapagos Nv Transaction History
Paradigm Biocapital Advisors LP
- $2.67 Billion
- Q1 2024
Shares
2 transactions
Others Institutions Holding GLPG
# of Institutions
90Shares Held
16.5MCall Options Held
77.1KPut Options Held
57.2K-
Eco R1 Capital, LLC San Francisco, CA5.76MShares$143 Million5.29% of portfolio
-
Bvf Inc San Francisco, CA1.86MShares$46.2 Million1.8% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY1.41MShares$35 Million0.94% of portfolio
-
Prosight Management, LP Dallas, TX932KShares$23.1 Million8.62% of portfolio
-
Segall Bryant & Hamill, LLC Chicago, IL868KShares$21.5 Million0.53% of portfolio
About GALAPAGOS NV
- Ticker GLPG
- Exchange OTC
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 65,835,500
- Market Cap $1.63B
- Description
- Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative coliti...